Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Fig. 2

The prediction ability of serum inflammation indexes to distinguish responders and non-responders (showing the serum inflammation indexes with poor prediction ability). A NLR at post treatment of first period; B LMR at post treatment of first period; C NLR at post treatment of second period; D NLR at post treatment of third period; E PLR at post treatment of first period; F PLR at post treatment of second period; G SII at post treatment of first period; H PLR at post treatment of third period

Back to article page